Acmg Criteria Calculator

Clinical Genetics Tool

Estimate a variant classification using a practical ACMG/AMP-style rules engine. Enter the number of pathogenic and benign evidence criteria at each strength level to generate a likely interpretation, summary, and visual evidence profile.

Variant Evidence Inputs

Expert Guide to Using an ACMG Criteria Calculator

An ACMG criteria calculator is a practical decision-support tool designed to help laboratories, clinicians, and genetics professionals organize variant evidence under the ACMG/AMP framework. The core purpose is not to replace expert review, but to make the evidence-combination process more transparent, reproducible, and easier to audit. When a sequence variant is found through exome sequencing, genome sequencing, multigene panels, or targeted testing, the next challenge is deciding whether the observed change is pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. That is where a structured calculator becomes valuable.

The 2015 ACMG/AMP guidance created a widely adopted approach for variant interpretation by grouping evidence into strength categories. On the pathogenic side, the categories include very strong, strong, moderate, and supporting evidence. On the benign side, the categories include stand-alone, strong, and supporting evidence. A calculator like the one above translates your entered evidence counts into one of the standard classes based on common combination rules. It can also provide a weighted summary score to help reviewers understand the overall direction and magnitude of the evidence, especially in difficult cases that cluster around uncertain significance.

Why the ACMG framework matters in clinical genetics

Clinical sequencing generates enormous amounts of data, but the value of that data depends on interpretation quality. Inconsistent classification can lead to unnecessary patient anxiety, inappropriate surveillance, missed diagnoses, or poor cascade testing decisions for family members. The ACMG framework improves consistency by standardizing how evidence is weighed. It also encourages analysts to distinguish between robust clinical or experimental findings and weaker contextual clues such as computational prediction. A calculator adds another layer of standardization by forcing the user to document how much evidence exists at each level before seeing a final category.

Importantly, the ACMG system was designed to be a general framework, not a substitute for disease-specific curation. Many expert panels have refined the original rules for particular genes, inheritance patterns, and phenotypes. That means any online calculator should be treated as a structured aid, not as a final authority. Laboratories often apply additional internal policies, gene-specific thresholds, and literature review standards before issuing a report.

What each evidence level means

• Very strong pathogenic: Usually represented by PVS1-like evidence, often involving a predicted loss-of-function variant in a gene where loss of function is an established disease mechanism.
• Strong pathogenic: Includes high-confidence evidence such as validated functional impact, convincing de novo findings, or a known amino acid change established as pathogenic through a different nucleotide event.
• Moderate pathogenic: Includes observations such as absence from controls, mutational hotspot location, occurrence in trans with a pathogenic variant in recessive disease, or moderate-quality functional support.
• Supporting pathogenic: Includes lower-weight evidence such as multiple computational predictions favoring a deleterious effect, phenotype specificity, or limited segregation evidence.
• Stand-alone benign: Typically BA1-level evidence, commonly driven by a population frequency that is too high to be compatible with the disorder.
• Strong benign: Robust evidence against pathogenicity, such as well-supported functional data showing no damaging effect or population observations inconsistent with disease causation.
• Supporting benign: Lower-weight benign observations, including computational evidence against impact or certain contextual observations in the right inheritance setting.

How this calculator classifies a variant

The calculator above follows practical ACMG-style combination logic. On the benign side, one stand-alone benign criterion usually supports a benign classification by itself. Alternatively, two or more strong benign criteria often indicate benign, while one strong plus one supporting benign criterion can support likely benign. On the pathogenic side, combinations such as one very strong plus one strong, one very strong plus two moderate, one very strong plus one moderate plus one supporting, or one very strong plus two supporting can satisfy pathogenic logic depending on the exact evidence mix. Likely pathogenic can be supported by combinations such as one very strong plus one moderate, one strong plus one to two moderate, one strong plus at least two supporting, or three moderate criteria. If neither the benign nor pathogenic combinations are met, the result generally remains a variant of uncertain significance.

This tool also reports a weighted evidence score. While the official ACMG framework is categorical rather than purely numerical, weighted scoring helps visualize how heavily the evidence leans in one direction. A simple point model often assigns greater weight to very strong and strong pathogenic evidence than to moderate or supporting evidence, while stand-alone and strong benign evidence strongly reduce the net score. That score should never be interpreted in isolation, but it can be useful when discussing borderline cases during case conferences, sign-out meetings, and quality review sessions.

Step-by-step workflow for reliable use

1. Define the variant precisely. Confirm transcript, nomenclature, zygosity, reference genome build, and whether the change affects a coding region, splice site, promoter, or untranslated region.
2. Review the disease mechanism. Determine whether loss of function, gain of function, dominant negative effect, or a different mechanism is relevant for the gene-disease pair.
3. Assess population frequency. Compare the variant to large population resources and evaluate whether observed frequency is compatible with disease prevalence, penetrance, and inheritance.
4. Review functional and segregation data. Prioritize validated assays, segregation patterns, de novo evidence, and case-level observations with enough detail to be trustworthy.
5. Apply disease-specific specifications when available. Expert panel modifications frequently refine when certain criteria should be upgraded, downgraded, or not used.
6. Enter criteria counts carefully. Avoid double counting the same observation under more than one rule, which is one of the most common interpretation errors.
7. Use the output as a support tool. Confirm that the result matches the underlying evidence narrative before incorporating it into a report.

Comparison of ACMG evidence strengths

Evidence tier	Typical ACMG label	General role	Relative weight in many point-based summaries
Pathogenic very strong	PVS	High-impact evidence with major influence on final classification	+8 points
Pathogenic strong	PS	Robust evidence from validated studies or highly persuasive case data	+4 points
Pathogenic moderate	PM	Intermediate evidence that often contributes in combination	+2 points
Pathogenic supporting	PP	Lower-level evidence useful when aggregated thoughtfully	+1 point
Benign stand-alone	BA	Evidence that can independently support benign classification	-8 points
Benign strong	BS	Substantial evidence against pathogenicity	-4 points
Benign supporting	BP	Additional low-weight benign support	-1 point

Real-world interpretation statistics and why calculators are useful

Variant interpretation is difficult because the evidence landscape changes continuously. Public databases illustrate this challenge. ClinVar, maintained by the National Center for Biotechnology Information, contains millions of submissions and aggregates interpretations from clinical laboratories, researchers, and expert panels. Across broad clinical sequencing programs, a meaningful proportion of reported variants remain in the uncertain significance category because available evidence is incomplete or conflicting. In inherited disease testing, variants of uncertain significance often appear more frequently than clearly pathogenic findings, especially in underrepresented populations where reference data and case series are less mature.

Population databases are equally important. The Genome Aggregation Database, commonly known as gnomAD, has compiled allele frequencies from hundreds of thousands of sequenced individuals. Large-scale resources of this kind dramatically reduce false pathogenic assertions because variants once thought rare may actually be too common to cause highly penetrant Mendelian disease. Even a simple ACMG calculator becomes far more reliable when its inputs are informed by current population-scale data and disease-specific frequency thresholds.

Data source	Useful scale statistic	Why it matters for ACMG interpretation
ClinVar	More than 2 million submitted records are publicly accessible in NCBI-maintained variant archives	Shows how often variants have existing assertions, conflicts, or expert review status
gnomAD	Aggregates sequencing data from hundreds of thousands of individuals across diverse ancestries	Supports BA1, BS1, PM2, and related frequency-based evidence decisions
Clinical sequencing programs	VUS rates can be substantial and vary by test type, disease area, and ancestry representation	Highlights the need for standardized evidence combination and periodic reinterpretation

Common mistakes when applying ACMG criteria

• Double counting evidence. The same case observation should not be used to justify multiple criteria unless the specification explicitly allows it.
• Ignoring gene mechanism. A truncating variant does not automatically deserve very strong evidence if loss of function is not an established disease mechanism.
• Misusing population frequencies. Frequency cutoffs must be compatible with disease prevalence, penetrance, and inheritance, not applied generically.
• Overvaluing computational predictions. In silico evidence is usually supporting, not decisive, unless a specialized specification says otherwise.
• Treating all functional assays equally. Assay relevance, validation quality, and reproducibility are critical.
• Neglecting phenotype specificity. A strong genotype-phenotype match can matter, but vague clinical overlap should not be overinterpreted.

How to use authoritative databases alongside this calculator

For best results, pair the calculator with primary evidence sources rather than relying on memory or secondary summaries. ClinVar is useful for previous submissions and conflict review. MedGen and GeneReviews can help confirm disease associations and inheritance patterns. gnomAD supports allele frequency assessment across ancestries. The National Human Genome Research Institute and university-hosted genetics resources provide educational guidance on variant interpretation and genomic medicine. If your case involves a gene with ClinGen expert panel specifications, those recommendations should usually take priority over generic assumptions.

Helpful authoritative references include the NCBI ClinVar database, the National Human Genome Research Institute, and the MedlinePlus Genetics educational resource. These sources are especially valuable for checking prior assertions, learning the biology behind a variant, and verifying whether a disease mechanism supports the criteria you intend to apply.

When to recalculate a variant classification

Variant interpretation is not static. Reanalysis is often appropriate when new functional studies are published, additional family segregation data emerges, population databases expand, disease mechanisms are refined, or expert panels release rule specifications. Laboratories with active reinterpretation programs often revisit selected variants periodically, especially uncertain significance results in clinically actionable genes. A calculator can simplify that process because it provides a structured record of which evidence categories changed and how the combination logic shifted over time.

Bottom line

An ACMG criteria calculator helps translate complex variant evidence into a transparent preliminary classification. Its greatest value lies in consistency, documentation, and speed. It is particularly useful during triage, peer review, and educational training because it forces users to think in evidence-strength categories rather than intuitive impressions. Still, no calculator can replace expert judgment, disease-specific specifications, or careful literature review. The best use case is as part of a larger interpretation workflow that includes phenotype review, mechanism assessment, database validation, and formal sign-out by qualified professionals.

This calculator is for educational and workflow support purposes only. It does not provide medical advice, does not substitute for ACMG/AMP guideline expertise, and should not be used as the sole basis for clinical reporting. Always verify criteria with current disease-specific specifications, validated laboratory procedures, and expert review.